Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846875 | 0.91 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL426628 | 0.91 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL12578568 | 0.81 | CRBN (0.48) | — | |
| SCHEMBL24271158 | 0.79 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL3225542 | 0.70 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL4774949 | 0.65 | KDM4E (0.35) | SMN1; SMN2 | |
| SCHEMBL5858590 | 0.63 | — | — | |
| SCHEMBL17727114 | 0.61 | OTUD7B (0.41) | SMN1; SMN2 | |
| SCHEMBL14016345 | 0.60 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL13144498 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626423-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4363416-A1 | MK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4225445-A2 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1660085-B1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1660475-B1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | disclosed |
| US-7279575-B2 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2007-10-09 | — | — | US | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660475-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014572-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | SMN1; SMN2 2469/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | SMN1; SMN2 3385/4885 |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | TYMP, DTYMK, DCK | SMN1; SMN2 2627/4885 |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | SMN1; SMN2 4343/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | SMN1; SMN2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.